Letter to the Editor | Published:

Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma

Leukemia volume 29, pages 19451948 (2015) | Download Citation

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , , , , , et al. Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantation. Leuk Lymphoma 2013; 54: 2200–2204.

  2. 2.

    , , , , , et al. Durable remission with salvage second autotransplants in patients with multiple myeloma. Cancer 2012; 118: 3549–3555.

  3. 3.

    , , , , , et al. Autologous stem cell transplantation: an effective salvage therapy in multiple myeloma. Biol Blood Marrow Transplant 2013; 19: 445–449.

  4. 4.

    , , , , , et al. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI myeloma × relapse (Intensive trial)): a randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15: 874–885.

  5. 5.

    , , , , , et al. Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial. Am J Hematol 2011; 86: 640–645.

  6. 6.

    , , , . Lenalidomide (Revlimid) combined with continuous oral cyclophosphamide (endoxan) and prednisone (REP) is effective in lenalidomide/dexamethasone-refractory myeloma. Br J Haematol 2010; 148: 335–337.

  7. 7.

    , , , , , et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467–1473.

  8. 8.

    , . Dose-finding based on efficacy-toxicity trade-offs. Biometrics 2004; 60: 684–693.

  9. 9.

    . On the interpretation of χ2 from contingency tables, and the calculation of P. J R Stat Soc 1922; 85: 87–94.

  10. 10.

    , . Note on exact treatment of contingency, goodness of fit and other problems of significance. Biometrika 1951; 38: 141–149.

  11. 11.

    , , . Bayesian Data Analysis 2nd edn. Chapman & Hall/CRC Press: New York, NY, USA, 2004.

  12. 12.

    , , . Bayesian Survival Analysis. Springer: New York, NY, 2001.

  13. 13.

    , , , , , et al. Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma. Leuk Lymphoma 2013; 54: 1465–1472.

  14. 14.

    . Novel agents for multiple myeloma to overcome resistance in phase III clinical trials. Semin Oncol 2013; 40: 634–651.

  15. 15.

    , , , , , et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 2012; 26: 149–157.

Download references

Author information

Affiliations

  1. Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    • N Shah
    • , Q Bashir
    • , S Parmar
    • , P Kebriaei
    • , Y Nieto
    • , U R Popat
    • , C M Hosing
    • , A Cornelison
    • , E J Shpall
    • , R E Champlin
    •  & M H Qazilbash
  2. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    • P F Thall
    •  & P S Fox
  3. Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    • J J Shah
    •  & R Z Orlowski
  4. Department of Hematopatholoy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    • P Lin

Authors

  1. Search for N Shah in:

  2. Search for P F Thall in:

  3. Search for P S Fox in:

  4. Search for Q Bashir in:

  5. Search for J J Shah in:

  6. Search for S Parmar in:

  7. Search for P Lin in:

  8. Search for P Kebriaei in:

  9. Search for Y Nieto in:

  10. Search for U R Popat in:

  11. Search for C M Hosing in:

  12. Search for A Cornelison in:

  13. Search for E J Shpall in:

  14. Search for R Z Orlowski in:

  15. Search for R E Champlin in:

  16. Search for M H Qazilbash in:

Competing interests

Drs N Shah, Bashir, JJ Shah, Hosing and Orlowski receive research funding from Celgene. Drs N Shah, JJ Shah and Orlowski have served on Celgene Advisory Boards.

Corresponding author

Correspondence to N Shah.

Supplementary information

Word documents

  1. 1.

    Supplementary Table 1

About this article

Publication history

Published

DOI

https://doi.org/10.1038/leu.2015.54

Supplementary Information accompanies this paper on the Leukemia website (http://www.nature.com/leu)

Further reading